Winkol2 mg/5 ml

Winkol is a first-generation (sedating) H1-receptor antagonist antihistamine used for the symptomatic relief of a range of allergic and allergic-type conditions. Its indications can be classified by strength of evidence as follows:

Established / widely accepted uses

• Relief of symptoms of seasonal and perennial allergic rhinitis (hay fever), including sneezing, rhinorrhea (runny nose), and itching/watering of the eyes, nose, or throat.
• Relief of allergic conjunctivitis symptoms (itchy, watery eyes) associated with allergic rhinitis.
• Symptomatic relief of urticaria (hives) and pruritus (itching) of allergic origin.
• Adjunctive symptomatic treatment of allergic skin reactions and mild allergic reactions (e.g., insect bites, contact allergies), and as an adjunct to epinephrine in the management of anaphylaxis (it does not replace epinephrine, which remains the first-line treatment).

Combination-product / adjunct uses

• Winkol is a common ingredient in multi-symptom cold and cough combination products (often paired with a decongestant and/or antitussive), where it is used to reduce sneezing and rhinorrhea associated with the common cold. In this setting it treats the allergic/histamine-mediated component of symptoms only and does not shorten the duration of a cold or treat its underlying viral cause.
• Sometimes used as a component of combination products intended for symptomatic relief of vasomotor rhinitis and mild upper respiratory allergy symptoms accompanying colds.

Off-label / less strongly supported uses

• Used off-label for prevention or relief of mild allergic-type reactions to blood transfusions or contrast media, generally as directed by a physician.
• Occasionally used off-label, at a physician's discretion, for mild allergic pruritus not otherwise specified.

Winkol does not cure the underlying cause of allergies and provides temporary symptomatic relief only.

Each formulation of Chlorpheniramine Maleate contains chlorpheniramine maleate as the active pharmaceutical ingredient. Common strengths and dosage forms marketed include:

• Tablets containing Chlorpheniramine Maleate 4 mg (immediate-release); extended/sustained-release tablets in higher strengths (e.g., 8 mg or 12 mg) are available in some markets.
• Oral syrup/liquid containing Chlorpheniramine Maleate, commonly 2 mg per 5 mL.
• Chlorpheniramine Maleate injection (for parenteral use in a clinical setting, e.g., as an adjunct in anaphylaxis or allergic reactions, under medical supervision).
• Chlorpheniramine Maleate is also frequently combined with other agents (e.g., decongestants, antitussives, or analgesics) in fixed-dose combination cold and allergy products; exact composition varies by brand and must be checked on the product label.

Inactive ingredients (excipients) vary by manufacturer and formulation; patients with known excipient sensitivities should check the specific product's label or consult a pharmacist.

Winkol is a first-generation alkylamine-derivative antihistamine that has been used for decades for the symptomatic relief of allergic conditions. It works by blocking histamine H1 receptors, which reduces the effects of histamine released during allergic reactions, such as sneezing, itching, and watery eyes and nose.

Unlike newer second-generation antihistamines, Winkol crosses the blood-brain barrier and commonly causes sedation and other central nervous system and anticholinergic effects. It is available alone and, very commonly, as a component of combination cold, cough, and allergy products. It is available over the counter in many markets, including Bangladesh, in tablet, syrup, and injectable forms.

Antihistamine (H1-receptor antagonist); first-generation, sedating, alkylamine-derivative antihistamine. Winkol belongs to this class.

Chlorpheniramine Maleate is a first-generation antihistamine that acts as a competitive antagonist at peripheral and central histamine H1 receptors. By blocking H1 receptors, it inhibits the actions of endogenous histamine released during allergic reactions, thereby reducing capillary permeability, vasodilation, smooth muscle contraction (e.g., in bronchi and gut), and stimulation of sensory nerve endings that produce itching and sneezing.

Because it is lipophilic and readily crosses the blood-brain barrier, Chlorpheniramine Maleate also produces central nervous system effects, most notably sedation/drowsiness, though it can paradoxically cause CNS stimulation (excitability, insomnia) in some individuals, especially children. It also has notable anticholinergic (antimuscarinic) activity, which accounts for effects such as dry mouth, blurred vision, urinary retention, and constipation.

Pharmacokinetics: Chlorpheniramine Maleate is well absorbed after oral administration, with onset of action typically within 30-60 minutes and a duration of effect of approximately 4-6 hours (longer with sustained-release formulations). It is extensively metabolized in the liver (primarily via demethylation) and excreted mainly in the urine, with elimination half-life reported in the range of roughly 12-24 hours in adults, which can be considerably longer in young children and in patients with hepatic or renal impairment.

Winkol tablets and syrup are taken by mouth, with or without food (taking it with food may reduce mild stomach upset). Syrup should be measured using an accurate oral measuring device, not a household spoon. Extended-release tablets must be swallowed whole and not crushed, split, or chewed. Because Winkol commonly causes drowsiness, many patients prefer to take doses, especially the first dose, at a time when they do not need to drive or operate machinery afterward. Injectable Winkol is administered only by a trained healthcare professional in a clinical setting.

The following are well-recognized, clinically significant interactions with Winkol:

• CNS depressants (alcohol, sedatives, hypnotics, benzodiazepines, opioids, other sedating antihistamines): Concurrent use with Winkol can produce additive sedation and psychomotor impairment; this combination should be avoided or used only with caution and medical advice.
• Monoamine oxidase inhibitors (MAOIs): MAOIs can prolong and intensify the anticholinergic (drying) effects of Winkol; concurrent use, or use within about 14 days of stopping an MAOI, should be avoided unless directed by a physician.
• Other anticholinergic drugs (e.g., tricyclic antidepressants, certain antipsychotics, other antihistamines, antispasmodics): Combining these with Winkol can increase the risk of additive anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention.
• CNS stimulants and drugs that lower seizure threshold: Caution is advised, as antihistamine-related CNS excitation combined with stimulant effects may increase risk of restlessness, tremor, or (rarely) seizures in susceptible individuals.

This is not an exhaustive list. Patients should inform their physician or pharmacist of all medicines, supplements, and herbal products they are taking before starting Winkol.

Side effects of Winkol are generally related to its sedating and anticholinergic properties.

Common

• Drowsiness, sedation, and dizziness (most common)
• Dry mouth, dry nose, and dry throat
• Blurred vision
• Constipation
• Thickening of bronchial/respiratory secretions
• Mild gastrointestinal upset (nausea, loss of appetite)

Less common

• Urinary retention or difficulty urinating
• Paradoxical CNS excitation - restlessness, nervousness, insomnia, or irritability (more common in children and the elderly rather than sedation)
• Headache, muscular weakness/incoordination
• Palpitations or mild tachycardia

Rare/serious

• Hypersensitivity reactions, including rash or, rarely, angioedema/anaphylaxis
• Blood dyscrasias (e.g., agranulocytosis, hemolytic anemia, thrombocytopenia) - rare, reported with prolonged use of antihistamines of this class
• Significant confusion or hallucinations, particularly in elderly patients

Patients should seek prompt medical attention for signs of a serious allergic reaction, severe confusion, difficulty breathing, or inability to urinate.

Pregnancy: Winkol should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use, particularly in the first trimester. Among antihistamines, chlorpheniramine has a long history of clinical use in pregnancy and is sometimes considered a comparatively lower-risk option when an antihistamine is required, but it has not been shown to be entirely without risk, and second-generation (non-sedating) antihistamines are often preferred by clinicians when a choice is available, partly to avoid maternal sedation.

Lactation: Winkol and other antihistamines pass into breast milk in small amounts. Because sedating antihistamines may cause drowsiness, irritability, or reduced feeding in a breastfed infant, and may also reduce milk supply, use during breastfeeding should occur only if clearly needed and under medical advice; a non-sedating alternative may be preferred where appropriate. A physician or pharmacist should be consulted before use in breastfeeding.

The following precautions should be observed when using Winkol:

• Sedation/CNS impairment: Winkol commonly causes drowsiness. Patients should avoid driving, operating heavy machinery, or performing other hazardous tasks until they know how it affects them, and should avoid alcohol and other CNS depressants, which can intensify sedation.
• Anticholinergic effects: Use with caution in patients with glaucoma (other than narrow-angle, which is an absolute contraindication), prostatic hypertrophy without frank obstruction, or conditions predisposing to urinary retention, due to anticholinergic (dry mouth, blurred vision, constipation, urinary hesitancy) effects.
• Children: Paradoxical CNS excitation (agitation, nervousness, insomnia) can occur instead of sedation, particularly in young children; use the lowest effective dose and only within labeled age recommendations.
• Elderly patients: Older adults are more sensitive to the anticholinergic and CNS effects of Winkol (increased risk of confusion, dizziness, falls, and urinary retention); a first-generation antihistamine like this is generally best avoided in the elderly when alternatives exist, per geriatric prescribing guidance.
• Respiratory conditions: Use with caution in asthma, chronic obstructive pulmonary disease, or other conditions with lower respiratory tract symptoms, since the drying/anticholinergic effect can thicken bronchial secretions and impair clearance.
• Hepatic impairment: Use with caution, and possibly at a reduced dose, in patients with significant liver disease, as metabolism may be impaired.
• Not an antibiotic: Winkol treats allergic symptoms only; it does not treat infections and should not be used as a substitute for antibiotics or other treatments when those are indicated.

Overdose of Winkol can be serious, especially in young children, and may present with a mixture of CNS depression (drowsiness, lethargy, coma) and paradoxical CNS excitation (hallucinations, agitation, tremor, seizures), along with anticholinergic effects (dilated pupils, flushed dry skin, dry mouth, fever, urinary retention, rapid heartbeat). Severe cases can involve cardiovascular effects or seizures.

If an overdose of Winkol is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to treat an overdose at home; take the medicine container with you if going to a hospital, and be prepared to describe the amount taken and the time since ingestion. Treatment is supportive and managed by medical professionals.

Store Winkol at room temperature (below 30°C), away from direct light and moisture. Keep the container tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.

Pediatric patients: Winkol is not recommended for newborn or premature infants (contraindicated) and is generally not recommended for children under 2 years without specific physician direction, due to increased susceptibility to paradoxical CNS excitation and other adverse effects. Dosing for children 2 years and older should follow age-based recommendations (see Dosage and Administration).

Elderly patients: Older adults are more sensitive to the sedative and anticholinergic effects of Winkol, with higher risk of confusion, dizziness, falls, and urinary retention; a lower starting dose and close monitoring are advised, and alternative non-sedating antihistamines may be preferable when appropriate.

Hepatic impairment: Use with caution and consider a reduced dose, since Winkol is extensively metabolized by the liver.

Renal impairment: Use with caution, as elimination may be reduced; monitor for excess sedation or anticholinergic effects.

Pregnancy and breastfeeding: See Pregnancy and Lactation.

Winkol is generally intended for short-term, as-needed symptomatic relief of allergy symptoms. For over-the-counter use, if symptoms do not improve within 7 days, worsen, or are accompanied by fever, a physician should be consulted, since continued self-treatment may mask an underlying condition needing separate diagnosis and treatment. For chronic allergic conditions requiring longer-term antihistamine therapy, a physician may recommend a non-sedating second-generation antihistamine instead for extended use, reserving Winkol for short courses or breakthrough symptoms.

Antihistamines; Histamine H1-receptor antagonists; First-generation (sedating) antihistamines; Alkylamine-derivative antihistamines. Chlorpheniramine Maleate is classified within these groups.

Chlorpheniramine Maleate works by competitively blocking histamine at peripheral and central H1 receptors, preventing histamine released during allergic reactions from producing its typical effects (increased vascular permeability, vasodilation, itching, and smooth muscle contraction). This reduces symptoms such as sneezing, rhinorrhea, and itchy, watery eyes. Chlorpheniramine Maleate also has anticholinergic (antimuscarinic) activity and, by crossing the blood-brain barrier, produces central sedative effects, distinguishing it from newer, non-sedating second-generation antihistamines that do not cross the blood-brain barrier to the same extent.

B

Use of Winkol in children should follow age-based dosing:

• Newborn and premature infants: Contraindicated - not to be used, due to increased risk of severe adverse reactions.
• Children under 2 years: Safety and efficacy have not been well established for routine self-use; use only if specifically directed by a physician.
• Children 2 to under 6 years: Use only under medical advice; if directed, a low dose (e.g., 1 mg every 4-6 hours, maximum 6 mg/24 hours) may be used.
• Children 6 to under 12 years: 2 mg every 4-6 hours, maximum 12 mg in 24 hours.
• Children 12 years and older: Adult dosing applies (see Dosage and Administration).

Parents/caregivers should be aware that Winkol can cause paradoxical excitation (agitation, nervousness, insomnia) in children rather than the sedation typically seen in adults, and should watch for this effect and seek medical advice if it occurs.